A. Moreno

Infusion of haplo‐identical killer immunoglobulin‐like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation

B. Barlogie, G. Tricot, K. Hsu, 2008, British journal of haematology.

Immunization With a Recombinant MAGE-A3 Protein After High-dose Therapy for Myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2007, Journal of immunotherapy.

Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation.

B. Barlogie, G. Tricot, F. van Rhee, 2005, Cytotherapy.

Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.

B. Barlogie, G. Tricot, R. Batchu, 2005, Cancer research.

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.

F. Zhan, J. Shaughnessy, G. Tricot, 2005, Blood.

induces spontaneous humoral and cellular immune responses NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and

F. Zhan, J. Shaughnessy, G. Tricot, 2013 .

Killer Immunoglobulin-Like Receptor Ligand (KIR-Lig) Mismatched Natural Killer (NK) Cell Transfusions for Multiple Myeloma (MM).

B. Barlogie, J. Shaughnessy, G. Tricot, 2005 .